Table 1. Pretreatment with 10 nM... | American Society of Hematology

Table 1.

Pretreatment with 10 nM CEP-701, followed by addition of chemotherapy

	Cytarabine			Daunorubicin			Etoposide
	IC_50, μM	CI	IC_50, nM	CI	IC_50, nM	CI	IC_50, nM	CI
MV4-11	3256	1.168	29	0.922	171	1.4888	7	0.819
BaF3/ITD	2058	3.35	53	0.951	229	1.025	4	1.165
HL60	875	1.069	109	0.901	2396	0.922	47	0.977

	Cytarabine			Daunorubicin			Etoposide
	IC_50, μM	CI	IC_50, nM	CI	IC_50, nM	CI	IC_50, nM	CI
MV4-11	3256	1.168	29	0.922	171	1.4888	7	0.819
BaF3/ITD	2058	3.35	53	0.951	229	1.025	4	1.165
HL60	875	1.069	109	0.901	2396	0.922	47	0.977

IC₅₀ and CI values for the combination of 10 nM CEP-701 and chemotherapeutic agents at doses corresponding to the approximate IC₅₀. In this pretreatment scenario, triplicate samples of cells were exposed to CEP-701 for 24 hours and then transferred into medium containing both CEP-701 and the chemotherapeutic agent. MTT assays were then performed 48 hours later. Each CI value (generated by the Calcusyn program) was obtained by conducting dose-response experiments for CEP-701 and the indicated chemotherapy individually and in combination over a range of doses for both drugs. The values shown are representative of 3 different experiments.

View Large

This Feature Is Available To Subscribers Only